Clinical feasibility of remote intermittently scanned continuous glucose monitoring in coronavirus disease 2019 patients with and without diabetes during dexamethasone therapy

Endocrine journal

article

Naoya Shimizu¹  Akinori Hayashi²  Shiori Ito¹  Agena Suzuki¹  Rei Fujishima¹  Kenta Matoba¹  Tatsuhiko Wada³  Koji Takano¹  Masato Katagiri⁴  Masayoshi Shichiri¹ 

[1] Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine;Department of Laboratory Medicine, Kitasato University School of Medicine;Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine;Department of Respiratory Medicine, Kitasato University Hospital

关键词: Coronavirus disease 2019;    Device accuracy;    Intermittently scanned continuous glucose monitoring;    Remote continuous glucose monitoring;    Dexamethasone;   

DOI  :  10.1507/endocrj.EJ21-0540

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

The clinical utility of intermittently scanned continuous glucose monitoring (isCGM) in patients with coronavirus disease 2019 (COVID-19) is unclear. Hence, we investigated the accuracy of isCGM in COVID-19 patients during dexamethasone therapy. We evaluated the accuracy of the FreeStyle Libre via180 mg/dL, respectively. When divided according to the presence and absence of diabetes, both groups of paired glucose measurements showed a good correlation (56.3% and 43.7%, and 27.1% and 72.9% within the A and B areas in patients with and without diabetes, respectively), but the MARD was not significant but higher in patients without diabetes (16.5% and 24.2% in patients with and without diabetes). In conclusion, although isCGM may not be as accurate as traditional blood glucose monitoring, it has good reliability in COVID-19 patients with and without diabetes during dexamethasone therapy.

【 授权许可】

Unknown